WO2017158184A3 - Antivirale immuntherapie durch membranrezeptorligation - Google Patents

Antivirale immuntherapie durch membranrezeptorligation Download PDF

Info

Publication number
WO2017158184A3
WO2017158184A3 PCT/EP2017/056443 EP2017056443W WO2017158184A3 WO 2017158184 A3 WO2017158184 A3 WO 2017158184A3 EP 2017056443 W EP2017056443 W EP 2017056443W WO 2017158184 A3 WO2017158184 A3 WO 2017158184A3
Authority
WO
WIPO (PCT)
Prior art keywords
membrane receptor
viral infection
lymphocytes
cytotoxic agent
receptor ligation
Prior art date
Application number
PCT/EP2017/056443
Other languages
English (en)
French (fr)
Other versions
WO2017158184A2 (de
Inventor
Michael Schindler
Marius CODREA
Sven NAHNSEN
Herwig KOPPENSTEINER
Original Assignee
Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet filed Critical Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
Priority to JP2018549270A priority Critical patent/JP7303631B2/ja
Priority to AU2017235611A priority patent/AU2017235611B2/en
Priority to EP17711660.5A priority patent/EP3430048A2/de
Priority to CN201780017932.9A priority patent/CN109071661A/zh
Priority to RU2018134022A priority patent/RU2773427C2/ru
Publication of WO2017158184A2 publication Critical patent/WO2017158184A2/de
Publication of WO2017158184A3 publication Critical patent/WO2017158184A3/de
Priority to US16/131,325 priority patent/US11208469B2/en
Priority to US17/541,134 priority patent/US20220153816A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft ein zytotoxisches Agens zur Prophylaxe und/oder Behandlung einer Virusinfektion, das zur selektiven Bindung an einen Membranrezeptor virusinfizierter T-Lymphozyten ausgebildet ist, eine dieses zytotoxische Agens enthaltende pharmazeutische Zusammensetzung, die Verwendung des zytotoxischen Agens' zur Prophylaxe und/oder Behandlung von Virusinfektion, ein Verfahren zum Auffinden von zytotoxischen Agenzien, die Verwendung eines Membranrezeptors virusinfizierter T-Lymphozyten, der gegenüber nicht-infizierten T-Lymphozyten überexprimiert ist, zur Diagnose einer Virusinfektion, sowie ein Verfahren zur Diagnose einer Virusinfektion.
PCT/EP2017/056443 2016-03-18 2017-03-17 Antivirale immuntherapie durch membranrezeptorligation WO2017158184A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2018549270A JP7303631B2 (ja) 2016-03-18 2017-03-17 膜受容体への結合による抗ウイルス免疫療法
AU2017235611A AU2017235611B2 (en) 2016-03-18 2017-03-17 Antiviral immunotherapy by membrane receptor ligation
EP17711660.5A EP3430048A2 (de) 2016-03-18 2017-03-17 Antivirale immuntherapie durch membranrezeptorligation
CN201780017932.9A CN109071661A (zh) 2016-03-18 2017-03-17 通过膜受体连接的抗病毒免疫疗法
RU2018134022A RU2773427C2 (ru) 2016-03-18 2017-03-17 Противовирусная иммунотерапия посредством лигирования мембранных рецепторов
US16/131,325 US11208469B2 (en) 2016-03-18 2018-09-14 Antiviral immunotherapy by membrane receptor ligation
US17/541,134 US20220153816A1 (en) 2016-03-18 2021-12-02 Antiviral immunotherapy by membrane receptor ligation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102016105069.5 2016-03-18
DE102016105069.5A DE102016105069A1 (de) 2016-03-18 2016-03-18 Antivirale Immuntherapie durch Membranrezeptorligation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/131,325 Continuation US11208469B2 (en) 2016-03-18 2018-09-14 Antiviral immunotherapy by membrane receptor ligation

Publications (2)

Publication Number Publication Date
WO2017158184A2 WO2017158184A2 (de) 2017-09-21
WO2017158184A3 true WO2017158184A3 (de) 2017-11-09

Family

ID=58358614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/056443 WO2017158184A2 (de) 2016-03-18 2017-03-17 Antivirale immuntherapie durch membranrezeptorligation

Country Status (7)

Country Link
US (2) US11208469B2 (de)
EP (1) EP3430048A2 (de)
JP (1) JP7303631B2 (de)
CN (1) CN109071661A (de)
AU (1) AU2017235611B2 (de)
DE (1) DE102016105069A1 (de)
WO (1) WO2017158184A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021296450A1 (en) 2020-06-25 2022-10-20 The Procter & Gamble Company Aptamers for personal health care applications
CN115820650A (zh) * 2022-11-11 2023-03-21 湖南大学 一种特异性识别并结合整合素α4的核酸适体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120141465A1 (en) * 2006-10-04 2012-06-07 La Jolla Institute For Allergy And Immunology Virus vaccination and treatment methods with ox40 agonist compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650020B1 (de) 1993-10-20 1999-04-07 Isuzu Ceramics Research Institute Co., Ltd. Keramisches Heizelement und Herstellungsverfahren dafür
AU2873999A (en) 1998-02-24 1999-09-06 Sisters Of Providence In Oregon Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
DE60317677T2 (de) * 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
ES2457067T3 (es) 2005-05-06 2014-04-24 Providence Health System Proteína de fusión OX40-inmunoglobulina trimérica y métodos de uso
KR20080080639A (ko) 2005-12-16 2008-09-04 제넨테크, 인크. 항-ｏｘ40ｌ 항체 및 그의 사용 방법
DK2731677T3 (en) 2011-07-11 2018-06-18 Glenmark Pharmaceuticals Sa ANTIBODIES. BINDING TO OX40 AND THEIR USES
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CN105229032A (zh) 2013-03-18 2016-01-06 比奥塞罗克斯产品公司 人源化抗cd134(ox40)抗体及其应用
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP6637439B2 (ja) * 2014-03-31 2020-01-29 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
SG11201608106PA (en) * 2014-03-31 2016-10-28 Genentech Inc Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
UA124573C2 (uk) * 2015-09-25 2021-10-13 Дженентек, Інк. Антитіло, яке специфічно зв'язується з tigit людини, та спосіб лікування або сповільнення прогресування раку у суб'єкта

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120141465A1 (en) * 2006-10-04 2012-06-07 La Jolla Institute For Allergy And Immunology Virus vaccination and treatment methods with ox40 agonist compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMMARANOND PALANEE ET AL: "STUDY ON THE EXPRESSION OF CO-STIMULATORY MARKER CD134 ON CD4+ T CELLS IN HIV-1-INFECTED INDIVIDUALS", JOURNAL OF IMMUNOASSAY AND IMMUNOCHEMISTRY, vol. 33, no. 2, 1 April 2012 (2012-04-01), US, pages 195 - 202, XP055388096, ISSN: 1532-1819, DOI: 10.1080/15321819.2011.618861 *
W. JIANG ET AL: "Cycling Memory CD4+ T Cells in HIV Disease Have a Diverse T Cell Receptor Repertoire and a Phenotype Consistent with Bystander Activation", JOURNAL OF VIROLOGY., vol. 88, no. 10, 15 May 2014 (2014-05-15), US, pages 5369 - 5380, XP055388160, ISSN: 0022-538X, DOI: 10.1128/JVI.00017-14 *
WEINBERG A D ET AL: "Science gone translational: the OX40 agonist story", IMMUNOLOGICAL REVIEWS, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 244, no. 1, 1 November 2011 (2011-11-01), pages 218 - 231, XP002739167, ISSN: 0105-2896, [retrieved on 20111021], DOI: 10.1111/J.1600-065X.2011.01069.X *

Also Published As

Publication number Publication date
JP2019517995A (ja) 2019-06-27
WO2017158184A2 (de) 2017-09-21
AU2017235611A1 (en) 2018-10-04
DE102016105069A1 (de) 2017-09-21
US11208469B2 (en) 2021-12-28
EP3430048A2 (de) 2019-01-23
RU2018134022A (ru) 2020-04-20
JP7303631B2 (ja) 2023-07-05
CN109071661A (zh) 2018-12-21
AU2017235611B2 (en) 2020-05-28
US20220153816A1 (en) 2022-05-19
US20190077848A1 (en) 2019-03-14
RU2018134022A3 (de) 2020-04-20

Similar Documents

Publication Publication Date Title
PH12019500335A1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
NZ729150A (en) Antiretroviral agents
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12017500571A1 (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
PH12018500569A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
CR20190531A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
PH12017501272A1 (en) Indole derivatives as dengue viral replication inhibitors
MX2019011608A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
CR20190530A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
WO2017158184A3 (de) Antivirale immuntherapie durch membranrezeptorligation
EP4311575A3 (de) Methotrexat zur proliferativen vitreoretinopathie
PH12020550673A1 (en) Pyrazolopyrimidines having activity against the respiratory syncytial virus (rsv)
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
WO2016180826A8 (en) Influenza virus neutralizing peptidomimetic compounds
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
WO2016036252A3 (en) Hepatitis c virus specific antibody
EP3768681A4 (de) Hemmung von nsmase zur behandlung von hiv-infektionen
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018549270

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017235611

Country of ref document: AU

Date of ref document: 20170317

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017711660

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017711660

Country of ref document: EP

Effective date: 20181018

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17711660

Country of ref document: EP

Kind code of ref document: A2